Provided is a method for treating diseases related to cardiac tissue damage or cardiac insufficiency in a subject. The method includes the step of locally applying a mesenchymal stem cell sheet such as an umbilical cord mesenchymal stem cell sheet to the heart of the subject. Also provided are related use and compositions of the mesenchymal stem cell sheet.

The present invention relates to a cell preparation method that includes a step in which cells are applied to a polyimide porous film and cultivated, wherein the polyimide porous film is a polyimide porous film with a three-layer structure, having a surface layer A and a surface layer B that have a plurality of holes, and a macrovoid layer that is sandwiched between the surface layer A and the surface layer B, and the polyimide porous film is produced by a method including the following steps: (1) a step in which a poly(amic acid) solution comprising poly(amic acid) and an organic polar solvent is flow cast in a film shape and the result is immersed in or brought into contact with a coagulation medium to create a porous film of poly(amic acid); and (2) a step in which the porous film of poly(amic acid) obtained in step (1) is heat-treated and imidized.

The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.

Provided herein are, in various embodiments, methods and compositions for differentiating olfactory mucosa-derived mesenchymal stem cells (OM-MSC). In certain embodiments, the disclosure provides for media to differentiate OM-MSCs. In still further embodiments, the disclosure provides for methods and compositions using differentiated OM-MSCs for the treatment of nerve repair. In particular embodiments, the disclosure provides for novel treatments of peripheral nerve repair.

A method for enhancing the secretory function of mesenchymal stem cells and application thereof, belonging to the field of biotechnology. The present invention finds that the secretory function of umbilical cord mesenchymal stem cells (UCMSCs) can be remarkably promoted by pretreating the UCMSCs in vitro using sodium hyaluronate (HA), including increasing the secretion of cytokines such as HGF, SCF, EGF and VEGF, promoting activation of the PI3K-AKT signaling pathway and enhancing the repair of injury.

The present invention relates to a pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells.

A method is disclosed for separating cells from a lung. Mechanical pressure can be used in one stage of the process to increase the yield of separated cells, including alveolar type II cells.

An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, by which proliferation efficiency is improved so that a sufficient amount of synovium-derived mesenchymal stem cells can be obtained from a synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which is a method of producing a synovium-derived mesenchymal stem cell from a synovial tissue, where the production method includes treating the synovial tissue with a mixed enzyme including one or more kinds of collagenases and one or more kinds of neutral proteases for 2 hours or more without causing the synovial tissue to undergo a disinfection step.

An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, which makes it possible to obtain a sufficient amount of synovium-derived mesenchymal stem cells from the synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which includes treating a synovial tissue with an enzyme for 2 hours or more; and washing a mixture after the enzyme treatment until a residual enzyme concentration in a supernatant is 0.5 ng/mL or less, to obtain a synovium-derived mesenchymal stem cell.

The present invention relates to an anti-inflammatory agent comprising an extracellular vesicle that is obtained by a method of using a substance having an affinity for phosphatidylserine obtained from a mesenchymal stem cell-derived extracellular vesicle, as an active ingredient, and a method of producing an extracellular vesicle having an anti-inflammatory action, the method including a step of obtaining an extracellular vesicle from a mesenchymal stem cell-derived extracellular vesicle by a method in which a substance having an affinity for phosphatidylserine is used.